Skip to content

HealthEquity

US · HQY #1726 by market cap Listed 1970
94.75 -2.63 -2.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 4.30 Expensive vs history 96th percentile
5-year average 3.30 · #26 of 37 in Health Information Services
P/E ratio 37.35 In line with history 48th percentile
5-year average 1.80 · forward 31.95 · #5 of 16 in Health Information Services
P/S ratio 6.28 In line with history 42nd percentile
5-year average 6.45 · forward 5.82 · #29 of 41 in Health Information Services

Vs. peers Health Information Services

Company Market cap P/E (TTM) P/B Div yield
HealthEquity (HQY) 7.84B 34.21 3.94 0.00%
Veeva Systems (VEEV) 43.10B 43.64 5.80 0.00%
BrightSpring Health Services (BTSG) 12.50B 33.78 5.75 0.00%
Tempus AI (TEM) 9.86B -50.98 19.70 0.00%
Hinge Health (HNGE) 8.60B 51.68 28.71 0.00%
Doximity (DOCS) 5.13B 39.90 5.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value102.76 Economic moatNarrow UncertaintyMedium

Trading 8.5% below Morningstar's fair value estimate.

Fair value

HealthEquity Inc receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a medium uncertainty rating.

The firm's valuation metrics decrease our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 23.2%, which lies in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our balanced fair value estimate.

The firm's unfavorable dividend structure is an additional cause for concern. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, sits in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which further promotes our neutral price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is fairly-valued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

HealthEquity discussion 0 comments

Add a comment